The Effect of SARS-CoV-2 mRNA Vaccination on AMH Levels of Infertile Women

Eran Horowitz 1 Yossi Mizrachi 1 Hadas Ganer 1 Einat Oz 2 Amir Shalev 1 Jacob Farhi 1 Eldar Barber 1 Orna Schwartz 1 Arieh Raziel 1 Ariel Weissman 1
1OB/GYN, IVF UNIT, Wolfson M.C, Israel
2OB/GYN, Assuta M.C Ashdod, Israel

Research Question:
Does Pfizer-BioNTech SARS-Cov-2 mRNA vaccination affect the ovarian reserve of infertile patients undergoing IVF?

Design:
We conducted a prospective observational study at a single university-affiliated IVF unit, between November 2020 and September 2021. We included infertile women aged 18-44 undergoing IVF/ICSI who had received two SARS-Cov-2 mRNA vaccinations and had a baseline AMH level analyzed within the 12 months preceding their recruitment. We evaluated and compared AMH levels before and after the vaccination.

Results:
Overall, 31 patients were included in the study. The median AMH levels before and after Covid-19 vaccine were comparable (1.7 vs. 1.6 ng/ml, respectively, p=0.96). No correlation was found between patients’ anti-Covid-19 antibodies titer and the change in AMH levels.

Conclusion:
SARS-Cov-2 mRNA vaccination does not adversely affect the ovarian reserve, as evidenced by comparing serum AMH levels before and after vaccination. Our findings may serve as a counseling tool for clinicians in reassuring the safety of the SARS-Cov-2 mRNA vaccination in patients undergoing infertility treatment.